- Home
- BCTX vs MTVA Comparison
BCTX vs MTVA Comparison
Compare BCTX & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCTX
- MTVA
- Stock Information
- Founded
- BCTX 2014
- MTVA 2014
- Country
- BCTX Canada
- MTVA United States
- Employees
- BCTX N/A
- MTVA N/A
- Industry
- BCTX Biotechnology: Pharmaceutical Preparations
- MTVA
- Sector
- BCTX Health Care
- MTVA
- Exchange
- BCTX Nasdaq
- MTVA NYSE
- Market Cap
- BCTX 16.1M
- MTVA 15.1M
- IPO Year
- BCTX N/A
- MTVA N/A
- Fundamental
- Price
- BCTX $3.41
- MTVA $0.67
- Analyst Decision
- BCTX Strong Buy
- MTVA Strong Buy
- Analyst Count
- BCTX 1
- MTVA 2
- Target Price
- BCTX $32.00
- MTVA $7.50
- AVG Volume (30 Days)
- BCTX 791.2K
- MTVA 618.7K
- Earning Date
- BCTX 06-13-2025
- MTVA 05-14-2025
- Dividend Yield
- BCTX N/A
- MTVA N/A
- EPS Growth
- BCTX N/A
- MTVA N/A
- EPS
- BCTX N/A
- MTVA N/A
- Revenue
- BCTX N/A
- MTVA N/A
- Revenue This Year
- BCTX N/A
- MTVA N/A
- Revenue Next Year
- BCTX N/A
- MTVA N/A
- P/E Ratio
- BCTX N/A
- MTVA N/A
- Revenue Growth
- BCTX N/A
- MTVA N/A
- 52 Week Low
- BCTX $2.81
- MTVA $0.63
- 52 Week High
- BCTX $29.40
- MTVA $5.30
- Technical
- Relative Strength Index (RSI)
- BCTX 47.56
- MTVA N/A
- Support Level
- BCTX $2.81
- MTVA N/A
- Resistance Level
- BCTX $3.69
- MTVA N/A
- Average True Range (ATR)
- BCTX 0.28
- MTVA 0.00
- MACD
- BCTX 0.06
- MTVA 0.00
- Stochastic Oscillator
- BCTX 65.93
- MTVA 0.00
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
About MTVA METAVIA INC
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.